Cleveland Clinic in Cleveland, OH

The Research Center of Excellence is located in the Cleveland Clinic Lou Ruvo Center for Brain Health (LRCBH) on the Cleveland Clinic main campus, which provides diagnosis and ongoing treatment for patients with various neurocognitive disorders. The center is comprised of a multidisciplinary team of two behavioral neurologists, one geriatrician, one geriatric psychiatrist, two neuropsychologists, and three advance practice clinicians, in addition to a dedicated nursing and administrative staff. The team at the Cleveland Clinic has extensive experience with the treatment and management of patients with LBD. The center also has a full-time social worker to provide support and advice to patients and families in the clinic and runs a monthly LBD support group. In addition to the clinical staff, the research department is led by a research supervisor, three research nurses, 11 study coordinators, and two research assistants.


Clinic name: Cleveland Clinic Lou Ruvo Center for Brain Health
Name: Natalie Ehret
Email Address: ehretn@ccf.org
Phone Number: 216.445.0907
Contact this person for: Dementia with Lewy Bodies Consortium (DLBC) eligibility, enrollment, appointments, or LBD studies

Babak Tousi

Dr. Babak Tousi has dual fellowship training in geriatrics and movement disorders. He is the Head of the Clinical Trials Program at the Cleveland Clinic Lou Ruvo Center for Brain Health and an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.

Dr. Tousi’s clinical and research work focuses on neurodegenerative diseases, particularly Dementia with Lewy bodies (DLB), Alzheimer’s disease, and mild cognitive impairment. His research has contributed to understanding the clinical and diagnostic characteristics of these disorders, including the identification of color vision impairment as a feature in both the prodromal and dementia stages of Lewy body disease.

As a principal investigator, Dr. Tousi has led numerous clinical trials targeting Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia, helping to advance potential therapeutic interventions. He has been involved in designing and developing phase II–IV trials.